FdaApplication
BLA 125722
Identifiers
- fda_app_no: BLA125722
Properties
| Property | Value |
|---|---|
| applicant_name | PTC Therapeutics |
| application_type | BLA |
| approval_date | 2024-11-13 |
Revenue by product
KEBILIDI
| Period | Revenue |
|---|---|
| Q2 2026 | $11.2M |
| Q1 2026 | $9.6M |
| Q2 2025 | $11.9M |
| Q1 2025 | $8.7M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| KEBILIDI | — | 5.6x10^11VG/ML | Suspension |
1 product